# US 2008/0187938 A1 · ALDH1 As A Cancer Stem Cell Marker

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2008/0187938 A1
- Document ID: US20080187938A1
- Status: Published application
- Kind: A1
- Application number: 11/859,901
- Filed: 2007-09-24
- Published: 2008-08-07
- Earliest claimed: 2006-09-22
- Assignees: The Regents of the University of Michigan
- Inventors: Max S. Wicha; Gabriela Dontu; Christophe Ginestier; Emmanuelle Charafe-Jauffret; Suling Liu
- Web page: https://patentgrep.com/patent/US20080187938A1

## CPC

- G01N 33/57515: of the breast
- C12N 5/0693: {Tumour cells; Cancer cells}
- G01N 33/57535: of the large intestine, e.g. colon, rectum or anus
- G01N 2333/90203: acting on the aldehyde or oxo group of donors (1.2)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The present invention relates to compositions and methods for treating, characterizing, and diagnosing cancer. In particular, the present invention provides a novel stem cell cancer marker, ALDH1, useful for the diagnosis, characterization, and treatment of solid tumor stem cells.

## Claims

### Claim 1

A method of detecting solid tumor stem cells comprising;
a) contacting a tissue sample with an antibody or antibody fragment configured to detect ALDH1 expression in cells in said tissue sample; and
b) determining if said tissue sample contains solid tumor stem cells based on the presence or absence of ALDH1 expression in said tissue sample.

### Claim 2 (depends on 1)

The method of claim 1, wherein said tissue sample comprises breast cancer cells.

### Claim 3 (depends on 1)

The method of claim 1, wherein said tissue sample comprises colon cancer cells.

### Claim 4 (depends on 1)

The method of claim 1, wherein said tissue sample comprises inflammatory breast cancer cells.

### Claim 5 (depends on 1)

The method of claim 1, wherein said tissue sample is a parafin embedded sample.

### Claim 6 (depends on 1)

The method of claim 1, further comprising c) determining if said tissue sample contains low levels of BRCRA1 expression.

### Claim 7

A method for identifying a cancer patient with a poor prognosis, comprising:
a) obtaining a biological sample from said cancer patient comprising cancer cells;
b) treating said biological sample to determine if a portion of said cancer cells are ALDH1 expressing solid tumor stem cells, and
c) identifying said cancer patient as having a poor prognosis, wherein said identifying comprises demonstrating the presence of said ALDH1 expressing solid tumor stem cells in said biological sample.

### Claim 8 (depends on 7)

The method of claim 7, wherein said treating comprises contacting said biological sample with an antibody or antibody fragment specific for ALDH1.

### Claim 9 (depends on 7)

The method of claim 7, wherein said treating comprises contacting said biological sample with reagents configured to detecting expression of ALDH1 mRNA.

### Claim 10

A method for killing or inhibiting the proliferation of solid tumor stem cells comprising contacting said solid tumor stem cells with a biologically effective amount of a composition comprising at least one agent targeted to ALDH1.

### Claim 11 (depends on 10)

The method of claim 10, further comprising identifying the death of or the prevention of the growth of said solid tumor stem cells following said contacting.

### Claim 12 (depends on 10)

The method of claim 10, wherein said cell death is apoptosis.

### Claim 13

An isolated solid tumor stem cell, wherein: (a) the solid tumor stem cell is derived from a solid tumor; (b) the solid tumor stem cell expresses ALDH1; and (c) the solid tumor stem cell is tumorogenic.

### Claim 14 (depends on 13)

The isolated solid tumor stem cell of claim 13, wherein (d) the solid tumor stem cell over-expresses ERB2.

### Claim 15 (depends on 13)

The isolated solid tumor stem cell of claim 13, further wherein: (d) the solid tumor stem cell expresses the cell surface marker epithelial specific antigen (ESA).

### Claim 16 (depends on 13)

The isolated solid tumor stem cell of claim 13, further wherein: (d) the solid tumor stem cell expresses the cell surface marker epithelial specific antigen (ESA) and CD10.

### Claim 17 (depends on 13)

The isolated solid tumor stem cell of claim 13, further wherein: (d) the solid tumor stem cell does not expresses the cell surface marker epithelial specific antigen (ESA) or CD10.

### Claim 18 (depends on 13)

The isolated solid tumor stem cell of claim 13, wherein the solid tumor is a sarcoma cell or an epithelial cancer.

### Claim 19 (depends on 13)

The isolated solid tumor stem cell of claim 13, wherein the epithelial cancer is a breast cancer or an ovarian cancer.

### Claim 20 (depends on 13)

The isolated solid tumor stem cell of claim 13, wherein the solid tumor stem cell forms a new tumor upon transplantation into the host animal.
